Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 2/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741119 | 0.80 | TDP1 (0.64) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL11688741 | 0.78 | MAPT (0.46) | TSHRMAPTMEN1KMT2AALOX15 | |
| SCHEMBL9616612 | 0.78 | MEN1 (0.40) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL762576 | 0.77 | GAA (0.55) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL11691073 | 0.74 | ALDH1A1 (0.52) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL12705713 | 0.73 | CYP1A2 (0.58) | CA1CA2CA9MAPTKMT2A | |
| SCHEMBL2338559 | 0.73 | MAPT (0.66) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL6716129 | 0.73 | GAA (0.61) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL761988 | 0.73 | GAA (0.61) | TSHRTDP1CA1CA2CA9 | |
| SCHEMBL3125055 | 0.73 | TSHR (0.42) | TSHRTDP1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 853 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228488-A1 | EXTENDED RELEASE COMPOSITIONS AND PROCESS FOR PREPARATION | RUBICON RES PRIVATE LIMITED (IN) | 2021-07-29 | — | — | US | claimed |
| US-10716779-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2020-07-21 | — | — | US | claimed |
| US-20190262268-A1 | ORAL MODIFIED RELEASE FORMULATIONS | RUBICON RES PRIVATE LIMITED (IN) | 2019-08-29 | — | — | US | claimed |
| US-20190083465-A1 | Methods And Compositions For Treating Foot Or Hand Pain | SANDERS JENNIFER L (US) | 2019-03-21 | — | — | US | claimed |
| US-10195180-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2019-02-05 | — | — | US | claimed |
| WO-2018055641-A1 | ORAL MODIFIED RELEASE FORMULATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2018-03-29 | — | — | WO | claimed |
| US-20170128379-A1 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-05-11 | — | — | US | claimed |
| WO-2017027976-A1 | (±)5-8,12-ISOPROSTANE CLASS VI AS A MARKER FOR EARLY PREDICTION OF PRE-ECLAMPSIA | UNIVERSITé LAVAL (CA) | 2017-02-23 | — | — | WO | claimed |
| US-9526711-B2 | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | claimed |
| US-20160279086-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-09-29 | — | — | US | claimed |
| WO-2009151712-A2 | SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES | AUSPEX PHARMACEUTICALS. INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090247628-A1 | SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2007066068-A2 | CALCIUM ION CHANNEL RECEPTOR ANTAGONIST | THE UNIVERSITY OF HULL (GB) | 2007-06-14 | — | — | WO | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247628-A1 | SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES | CHRM3, CHRNG, CHRM5 | TSHR 440/4885TDP1 3360/4885CA1 868/4885 |
| US-20160279086-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | ADRB3, ADRB1, ADRA2C | TSHR 458/4885TDP1 4614/4885CA1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.